Company Overview of Edimer Pharmaceuticals Inc.
Edimer Pharmaceuticals Inc. develops and delivers solutions for the improvement in the health and quality of life to future generations living with X-linked hypohidrotic ectodermal dysplasia (XLHED). It offers EDI200, an ectodysplasin A replacement protein for the treatment of XLHED. The company was founded in 2009 and is based in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2009
Key Executives for Edimer Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Senior Director of Clinical Research
Director of Clinical Operations
Compensation as of Fiscal Year 2015.
Edimer Pharmaceuticals Inc. Key Developments
Edimer Pharmaceuticals Announces Completion of Dosing of the First Subject in the Second Cohort of the Ongoing Phase 2 Clinical Trial
May 28 14
Edimer Pharmaceuticals announced completion of dosing of the first subject in the second cohort of the ongoing Phase 2 clinical trial. Newborns in cohort 2 are administered the company's proprietary ectodysplasin replacement protein EDI200 at the dose (10 mg/kg) that was found to maximize response and health benefits in the preclinical model of XLHED. Prior to cohort 2 initiation, the independent Data Safety Monitoring Board (DSMB) reviewed safety data from cohort 1 neonates dosed at 3 mg/kg and approved the dose escalation. XLHED is an ultra-rare orphan disease of ectoderm development associated with a lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Affected individuals are at risk for serious and potentially life-threatening hyperthermia and respiratory infections. EDI200 replaces EDA-A1, the protein missing in XLHED and a key regulator of skin and tooth development. Following successful completion of a Phase 1 study of EDI200 in XLHED-affected adults, the Phase 2 clinical trial of EDI200 in XLHED-affected newborn male subjects is being conducted at several European and three U.S. medical centers. EDI200 dosing is initiated between the 2nd and 14(th) days of life, with each study subject receiving 2 doses per week for a total of 5 doses. Edimer expects the trial to be fully enrolled by the fourth quarter of 2014, with top-line data expected in the first half of 2015. If fully developed and approved, EDI200 will be the first protein therapeutic to provide a sustained correction of the symptoms of this disorder.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries